Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T)

  • Peter Bramlage, Bonner, Bernhard Landers
  • Vascular Health and Risk Management, February 2011, Taylor & Francis
  • DOI: 10.2147/vhrm.s17004

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Peter Bramlage